Education
About Us
Working with TipRanks
Follow Us
Senti Biosciences (SNTI)
NASDAQ:SNTI
SNTI Stock Chart & Stats
$1.02
-$0.36(-8.15%)
At close: 4:00 PM EST
$1.02
-$0.36(-8.15%)
Day’s Range― - ―
52-Week Range$1.00 - $5.10
Previous CloseN/A
Volume20.15K
Average Volume (3M)260.00K
Market Cap
$27.08M
Enterprise Value$44.17M
Total Cash (Recent Filing)$12.24M
Total Debt (Recent Filing)$30.12M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding26,290,838
10 Day Avg. Volume505,690
30 Day Avg. Volume260,000
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.39
Enterprise Value/Market Cap1.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.51
Enterprise Value/Ebitda-0.99
Forecast
1Y Price Target
$12.50Price Target Upside1125.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development And Regulatory RecognitionAnalyst points to RMAT designation, ongoing patient enrollment, and planned data presentations at major hematology meetings as catalysts that can boost visibility and support partnerships or further investment in development.
Platform And TechnologyAnalyst emphasizes Senti's Logic-Gated gene circuit and allogeneic CAR-NK design as a potential approach to address antigen targeting challenges and broaden the therapy's applicability across difficult-to-treat cancers.
Safety ProfileAnalyst highlights a differentiated safety profile for SENTI-202 with very mild immune-related toxicities, no dose-limiting toxicities reported, and rapid hematopoietic recovery that could expand patient eligibility compared with intensive chemotherapy.
Bears Say
Data RobustnessAnalyst cautions that the small patient sample in the SENTI-202 dataset creates uncertainty about the reproducibility and generalizability of the reported responses.
Efficacy Revision RiskAnalyst notes that the reported overall response rate was revised down from prior figures, which may temper confidence in the consistency of early efficacy metrics.
Financial PositionAnalyst flags significant financing risk, noting limited cash reserves of $12.2 million and the need to raise additional capital to fund ongoing clinical programs.
Senti Biosciences News
SNTI FAQ
What was Senti Biosciences’s price range in the past 12 months?
Senti Biosciences lowest stock price was $1.00 and its highest was $5.10 in the past 12 months.
What is Senti Biosciences’s market cap?
Senti Biosciences’s market cap is $27.08M.
When is Senti Biosciences’s upcoming earnings report date?
Senti Biosciences’s upcoming earnings report date is May 12, 2026 which is in 101 days.
How were Senti Biosciences’s earnings last quarter?
Senti Biosciences released its earnings results on Nov 13, 2025. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.567 by -$0.123.
Is Senti Biosciences overvalued?
According to Wall Street analysts Senti Biosciences’s price is currently Undervalued.
Does Senti Biosciences pay dividends?
Senti Biosciences does not currently pay dividends.
What is Senti Biosciences’s EPS estimate?
Senti Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senti Biosciences have?
Senti Biosciences has 26,290,838 shares outstanding.
What happened to Senti Biosciences’s price movement after its last earnings report?
Senti Biosciences reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.567. Following the earnings report the stock price went down -10.056%.
Which hedge fund is a major shareholder of Senti Biosciences?
Currently, no hedge funds are holding shares in SNTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senti Biosciences
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
SNTI Stock 12 Month Forecast
Average Price Target
$12.50
▲(1125.49% Upside)
Technical Analysis
Plus Therapeutics
―
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
IO Biotech
―
Ownership Overview
65.85% Insiders
2.56% Mutual Funds
17.74% Other Institutional Investors
11.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---